Physician profile
Jesse E Adams
NPI 1760470587
$4,339.51
in general payments reported to CMS, 2019-2025
28 companies · $873 in 2025
The $873 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $486 · 2020: $412 · 2021: $336 · 2022: $465 · 2023: $784 · 2024: $983 · 2025: $873.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,641.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,640.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $813.26 | 2019-2025 | |
| Pfizer INC. | $675.15 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $591.71 | 2019-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $533.78 | 2019-2024 | Xarelto |
| Amgen INC. | $316.14 | 2019-2025 | Repatha, Repatha |
| Abbott Laboratories | $205.52 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $176.40 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $165.31 | 2023-2025 | Farxiga, Brilinta, Andexxa |
| Alnylam Pharmaceuticals INC. | $157.69 | 2024-2025 | Onpattro |
| Bayer Healthcare Pharmaceuticals INC. | $118.31 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $113.68 | 2021-2025 | Verquvo |
| Novo Nordisk INC | $70.52 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $50.76 | 2020-2024 | |
| Davol INC. | $46.39 | 2019 | |
| Edwards Lifesciences Corporation | $40.33 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $37.16 | 2023 | Watchman Access System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $30.66 | 2019-2020 | |
| Kestra Medical Technology Services, INC. | $25.33 | 2025 | Assure Wcd |
| Regeneron Healthcare Solutions, INC. | $24.72 | 2019 | |
| Daiichi Sankyo INC. | $22.21 | 2025 | Injectafer |
| Kiniksa Pharmaceuticals, LTD. | $19.10 | 2023 | Arcalyst |
| Baxter Healthcare | $17.65 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Kowa Pharmaceuticals America, INC. | $17.27 | 2020 | |
| Irhythm Technologies, INC. | $16.57 | 2020 | |
| Philips North America LLC | $15.58 | 2025 | Mcot |
| Atricure, INC. | $15.37 | 2024 | |
| Astellas Pharma US INC | $11.49 | 2019 | |
| Amarin Pharma, INC. | $11.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.